| Literature DB >> 36158476 |
Sheng-Zhen Liu1, Ning-Li Chai1, Hui-Kai Li1, Xiu-Xue Feng1, Ya-Qi Zhai1, Nan-Jun Wang1, Ying Gao1, Fei Gao1, Sha-Sha Wang1, En-Qiang Linghu2.
Abstract
BACKGROUND: Conventional endoscopic papillectomy (EP) is safe and effective for the treatment of small papilla adenoma to even large laterally spreading tumors of duodenum lesions. As reported by some existing studies, temporarily placing a prophylactic stent in the pancreatic and bile duct can lower the risk of this perioperative complication. AIM: To evaluate the usefulness, convenience, safety, and short-term results of a novel autorelease bile duct supporter after EP procedure, especially the effectiveness in preventing EP.Entities:
Keywords: Adverse events; Bile duct stent; Duodenal papilla; Endoscopic papillectomy; Endoscopic retrograde cholangiopancreatography
Year: 2022 PMID: 36158476 PMCID: PMC9372830 DOI: 10.12998/wjcc.v10.i22.7785
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.534
Figure 1Endoscopic views of endoscopic papillectomy and autorelease biliary supporter placement in a patient with a laterally spreading tumors of the major duodenal papilla. A: Duodenal papilla tumor was examined by duodenoscopy with indigo carmine staining; B: Submucosal injection was performed to lift the lesion; C: Muscularis propria wound after piecemeal submucosal resection with duodenal papilla; D: The wound was closed with endoscopic hemoclips, and the novel autorelease bile stent was inserted via a guide wire by endoscopic retrograde cholangiopancreatography; E: Fibrin glue was sprayed to cover the wound; F: Specimen of piecemeal papilla polypectomy; G: X-ray image showed autorelease biliary stents were successfully placed; H: The autorelease biliary supporter fell off naturally and arrived in colon about 10 d after this operation.
Figure 2The novel autorelease bile supporter was inserted through a guide wire using endoscopic retrograde cholangiopancreatography.
Baseline characteristics of patients with papillary adenoma
|
|
|
|
|
|
| 1 | M | 59 | 20 | Tubular adenoma |
| 2 | M | 60 | 15 | Tubular adenoma and HGD |
| 3 | M | 49 | 32 | Adenomatoid hyperplasia and LGD |
| 4 | M | 44 | 20 | Tubular adenoma |
| 5 | M | 50 | 10 | Neuroendocrine tumor (stage G1) |
| 6 | F | 86 | 40 | HGD |
| 7 | M | 56 | 43 | Tubular adenoma and HGD |
| 8 | F | 52 | 20 | Tubular adenoma |
M: Male; F: Female; LGD: Low-grade dysplasia; HGD: High-grade dysplasia.
Endoscopic resection results at baseline and follow-up
|
|
|
|
|
|
|
|
|
|
|
| 1 | 5.495 | (+) | 11 |
| (+) | (-) | (+) | Mucosa | Tubulovillous adenoma/HGD |
| 2 | 8.635 | (+) | 27 |
| (-) | (-) | (-) | Submucosa | Tubulovillous adenoma/HGD |
| 3 | 9.734 | (+) | 21 |
| (+) | (-) | (+) | Mucosa | Adenomatoid hyperplasia/LGD |
| 4 | 6.28 | (+) | 8 |
| (+) | (-) | (+) | Mucosa | Tubular adenoma |
| 5 | 4.71 | (+) | 16 |
| (+) | (-) | (+) | Mucosa | Neuroendocrine tumor, stage G2 |
| 6 | 9.42 | (+) | 25 | Piecemeal | (+) | (-) | (+) | Muscularis mucosa | Tubular adenoma/HGD |
| 7 | 11.618 | (+) | 16 | Piecemeal | (+) | (-) | (+) | Submucosa | Tubulovillous adenoma/HGD |
| 8 | 4.71 | (+) | 13 |
| (+) | (-) | (+) | Mucosa | Tubular adenoma/LGD |
LGD: Low-grade dysplasia; HGD: High-grade dysplasia.